Baseline Characteristics of Participants in STAREE: A Randomized Trial for Primary Prevention of Cardiovascular Disease Events and Prolongation of Disability-Free Survival in Older People.

Autor: Zoungas S; School of Public Health and Preventive Medicine Monash University Melbourne Victoria Australia., Moran C; School of Public Health and Preventive Medicine Monash University Melbourne Victoria Australia.; Aged Care Services Alfred Health Melbourne Victoria Australia., Curtis AJ; School of Public Health and Preventive Medicine Monash University Melbourne Victoria Australia., Spark S; School of Public Health and Preventive Medicine Monash University Melbourne Victoria Australia.; Monash University Clinical Trials Centre, Faculty of Medicine Nursing and Health Sciences Monash University Melbourne Victoria Australia., Flanagan Z; School of Public Health and Preventive Medicine Monash University Melbourne Victoria Australia., Beilin L; School of Medicine Royal Perth Hospital, University of Western Australia Perth Western Australia Australia., Chong TT; Turner Institute for Brain and Mental Health, School of Psychological Sciences Monash University Melbourne Victoria Australia.; Department of Neurology Alfred Health Melbourne Victoria Australia.; Department of Clinical Neurosciences St Vincent's Hospital Melbourne Victoria Australia., Cloud GC; Department of Neurology Alfred Health Melbourne Victoria Australia.; Department of Neuroscience, School of Translational Medicine Monash University Melbourne Victoria Australia., Hopper I; School of Public Health and Preventive Medicine Monash University Melbourne Victoria Australia.; Department of Cardiology and General Medicine Unit Alfred Health Melbourne Victoria Australia., Kost A; School of Public Health and Preventive Medicine Monash University Melbourne Victoria Australia., McNeil JJ; School of Public Health and Preventive Medicine Monash University Melbourne Victoria Australia., Nicholls SJ; School of Public Health and Preventive Medicine Monash University Melbourne Victoria Australia.; Victorian Heart Institute, Monash University Clayton Victoria Australia., Reid CM; School of Public Health and Preventive Medicine Monash University Melbourne Victoria Australia.; School of Population Health Curtin University Perth Western Australia Australia., Ryan J; School of Public Health and Preventive Medicine Monash University Melbourne Victoria Australia., Tonkin AM; School of Public Health and Preventive Medicine Monash University Melbourne Victoria Australia., Ward S; School of Public Health and Preventive Medicine Monash University Melbourne Victoria Australia.; Centre for Healthy Brain Ageing, School of Psychiatry UNSW Sydney New South Wales Australia.; Department of Geriatric Medicine Prince of Wales Hospital Randwick New South Wales Australia., Wierzbicki AS; Department of Metabolic Medicine/Chemical Pathology Guy's & St Thomas' Hospitals London United Kingdom., Wolfe R; School of Public Health and Preventive Medicine Monash University Melbourne Victoria Australia., Zhou Z; School of Public Health and Preventive Medicine Monash University Melbourne Victoria Australia., Nelson MR; School of Public Health and Preventive Medicine Monash University Melbourne Victoria Australia.; Menzies Institute for Medical Research, University of Tasmania Hobart Tasmania Australia.
Jazyk: angličtina
Zdroj: Journal of the American Heart Association [J Am Heart Assoc] 2024 Nov 19; Vol. 13 (22), pp. e036357. Date of Electronic Publication: 2024 Nov 15.
DOI: 10.1161/JAHA.124.036357
Abstrakt: Background: The risk-benefit balance of statin use in healthy older people is uncertain. We describe the baseline characteristics of the STAREE (Statins in Reducing Events in the Elderly) trial, which is a randomized, double-blind, placebo-controlled trial among community-dwelling older people; the trial evaluated the effect of atorvastatin 40 mg for the prevention of major cardiovascular events (cardiovascular death, nonfatal myocardial infarction or stroke), and on disability-free survival (survival free of both dementia and persistent physical disability).
Methods and Results: STAREE enrolled people aged ≥70 years from 1583 general practices across Australia with no history of clinical cardiovascular disease, diabetes, or dementia. Baseline data collected included demographic, clinical, cognitive (Modified Mini-Mental State Examination), psychological (Center for Epidemiologic Studies Short Depression Scale), lifestyle, medical, physical, blood and urine measures, and quality of life. Demographic and clinical characteristics of study participants were then compared with publicly available landmark statin trials. A total of 9971 participants were recruited (mean±SD age 74.7±4.5 years, 4023 (40%) ≥75 years, 52% women) between July 2015 and March 2023. The mean low-density lipoprotein cholesterol was 3.27 mmol/L (SD=0.72; 126 mg/dL). Hypertension was reported by 43% of participants and the mean blood pressure was 136/80 mm Hg. Compared with previous landmark statin trials that included primary prevention cohorts, STAREE is unique in including such a large number of older (≥75 years) independent-living people.
Conclusions: STAREE is the largest primary prevention trial of statins powered to address the important clinical outcomes of major cardiovascular events, disability-free survival, and cognition in older people.
Registration: https://www.clinicaltrials.gov; Unique identifier: NCT02099123.
Databáze: MEDLINE
Externí odkaz: